[Stroma-targeted palliative tumor therapy with biomodulators]

Area of Science:

• Oncology
• Tumor Microenvironment Research
• Pharmacology

Background:

• Advanced tumors present therapeutic challenges, necessitating novel treatment strategies.
• Stroma-targeted approaches, particularly antiangiogenic therapies, are emerging as promising avenues.
• Certain biomodulating drugs, initially developed for non-oncologic indications, demonstrate significant antitumor effects.

Purpose of the Study:

• To explore the potential of biomodulating drugs in targeting tumor stroma for advanced cancer therapy.
• To evaluate the efficacy of combining these drugs for enhanced antitumor activity.
• To assess the role of these agents as supplementary or alternative palliative treatments.

Main Methods:

• Review of existing literature on biomodulating drugs with anti-stromal effects.
• Analysis of drug classes including thalidomide, COX-2 inhibitors, PPARgamma agonists, and mTOR antagonists.
• Evaluation of combination therapy strategies and their impact on tumor stroma.

Main Results:

• Biomodulating drugs like thalidomide, COX-2 inhibitors, PPARgamma agonists (thiazolidindiones), and mTOR antagonists (rapamycin) exert antitumor effects via indirect actions on tumor stroma.
• Combination therapies involving these agents appear more effective than monotherapies.
• These therapies offer a viable option for palliative treatment of advanced tumors.

Conclusions:

• Biomodulating drugs targeting tumor stroma represent a novel strategy for advanced cancer palliation.
• Combination therapy with these agents can enhance efficacy and patient outcomes.
• These approaches are well-tolerated, suitable for outpatient settings, and complement existing treatments.